Hepatitis C virus infection induced vasculitis.

Area of Science:

• Immunology
• Hepatology
• Rheumatology

Background:

• Cryoglobulinemia involves immune complexes causing systemic cryoglobulinemic vasculitis, affecting skin, joints, nerves, and kidneys.
• Hepatitis C virus (HCV) is the main cause of cryoglobulins, with risk factors including female gender, high alcohol intake, liver fibrosis, and steatosis.
• Symptomatic vasculitis correlates with older age, longer infection duration, and specific cryoglobulin characteristics (Type II, IgM kappa, high serum levels).

Purpose of the Study:

• To review the understanding of cryoglobulinemia and its associated vasculitis.
• To evaluate current and emerging therapeutic strategies for cryoglobulinemic vasculitis.
• To highlight the need for further clinical trials in managing this condition.

Main Methods:

• Literature review focusing on cryoglobulinemia, HCV, and vasculitis.
• Analysis of treatment outcomes for Peg-Interferon/Ribavirin and Rituximab therapies.
• Discussion of complex physiopathology involving immune responses.

Main Results:

• Peg-Interferon alpha and Ribavirin combination achieves a virological and clinical response in approximately 70% of patients.
• Rituximab demonstrates efficacy in nonresponders (up to 80% response rate), but with a notable relapse rate (42% after 7 months).
• The physiopathology involves humoral, B-cell, and T-cell immunity, not directly the virus itself.

Conclusions:

• Combination antiviral therapy (Peg-Interferon/Ribavirin) is effective for HCV-related cryoglobulinemic vasculitis.
• Rituximab is a viable option for nonresponders, though relapse necessitates further investigation.
• Future strategies should explore combining antiviral treatments with Rituximab, supported by mandatory multicenter controlled trials.